Claims
- 1. A compound of the structural formula ##STR216## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is
- aryl,
- C.sub.1-10 alkyl, or
- C.sub.4-10 aralkyl,
- wherein aryl is phenyl, pyridyl, thienyl, tetrazole or oxazale;
- R.sup.5 is ##STR217## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR218## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;
- Z is ##STR219## p is zero or one; and m is an integer from two to six.
- 2. A compound of claim 1, ##STR220## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is
- aryl,
- C.sub.1-10 alkyl, or
- C.sub.4-10 aralkyl,
- wherein aryl is phenyl, pyridyl, thiophenyl, tetrazole, or oxazole;
- R.sup.5 is ##STR221## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR222## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;
- Z is O;
- p is zero or one; and
- m is an integer from two to six.
- 3. A compound as claimed in claim 2, of the structural formula ##STR223##
- 4. A compound as claimed in claim 2, of the structural formula ##STR224##
- 5. A compound as claimed in claim 2, of the structural formula ##STR225##
- 6. A compound of claim 1 selected from the group consisting of
- 2-S-(2-Styrylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- 2-S-(Phenylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- 2-S-(2-Phenethylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- 2-S-(2-Thienylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]1-n-butylsulfonylamino)}ethanephosphonic acid ethyl ester;
- {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]1n-butylsulfonylamino)}ethanephosphonic acid; and
- Ethyl-2-S-Benzylsulfonylamino-3-[4-(piperidin-4-yl)butyloxyphenyl]propionate;
- 2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)-1,1-dimethyl-butyloxyphenyl]propionic acid; and
- 3-S-(Butylsulfonylamino)-4-[4-piperidin-4-yl)butyloxyphenyl]butanoic acid.
- 7. A pharmaceutical composition, comprising a compound as claimed in claim 2, and a pharmaceutically acceptable carrier.
- 8. A pharmaceutical composition, comprising the compound as claimed in claim 3, and a pharmaceutically acceptable carrier.
- 9. A pharmaceutical composition, comprising the compound as claimed in claim 4, and a pharmaceutically acceptable carrier.
- 10. A pharmaceutical composition, comprising the compound as claimed in claim 5, and a pharmaceutically acceptable carrier.
- 11. A pharmaceutical composition, comprising a compound as claimed in claim 6, and a pharmaceutically acceptable carrier.
- 12. A method of blocking fibrinogen from acting at its platelet receptor site in a mannal, comprising the step of administering to said mammal a pharmacologically effective amount of a compound as claimed in claim 2.
- 13. The method as claimed in claim 12, wherein said compound is ##STR226##
- 14. The method as claimed in claim 12, wherein said compound is ##STR227##
- 15. The method as claimed in claim 12, wherein said compound is ##STR228##
- 16. The method as claimed in claim 12, wherein said compound is selected from
- 2-S-(2-Styrylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- 2-S-(Phenylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid hydrochloride;
- 2-S-(2-Phenethylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- 2-S-(2-Thienylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride;
- {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]-1-n-butylsulfonylamino)}ethanephosphonic acid ethyl ester;
- {2-[4-[4-Piperidin-4-yl)butyloxyphenyl]-1-n-butylsulfonylamino)}ethanephosphonic acid; and
- Ethyl-2-S-Benzylsulfonylamino-3-[4-(piperidin-4-yl)butyloxyphenyl]propionate;
- 2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)-1,1-dimethyl-butyloxphenyl]propionic acid; and
- 3-S-(Butylsulfonylamino)-4-[4-piperidin-4-yl)butyloxyphenyl]butanoic acid.
CROSS-REFERENCE
This application is a continuation-in-part of U.S. Ser. No. 750,647, filed Aug. 30, 1991, now abandoned, which is a continuation-in-part of U.S. Ser. No. 589,130, filed Sep. 27, 1990, now abandoned.
US Referenced Citations (7)
Foreign Referenced Citations (2)
Number |
Date |
Country |
40111 |
Sep 1979 |
EPX |
449079-A |
Oct 1991 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Ruoslahti et al "New Perspectives in Cell Adhesion" Science 238 491-497 (1987). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
750647 |
Aug 1991 |
|
Parent |
589130 |
Sep 1990 |
|